Related Experiment Videos
[Antibiotic therapy in cystic fibrosis: uncertainty and reality]
Abstract:
Antibiotics inspite of certain contradictions remain an important part of the treatment of mucoviscidosis (MCV). Despite this the current practice of their extensive use does not always rest on firmly placed criteria. Before colonisation with pseudomonas (PA), the systemic prophylaxis of infection by Staphylococcus (SA), or Hemophilus (HI) is debatable. At the time of exacerbations, even if this may be caused by a virus, the prescription of antibiotics (ATB) active against SA and HI should often be continued for 2 or 3 weeks to maintain a durable clinical benefit. While awaiting the results of complimentary multi-centre trials at present underway it remains uncertain whether eradication of the germ at all costs remains indispensable. Systemic anti-PA antibiotic therapy given quarterly from the time of the implantation of the germ has not yet proved to have definitive advantages when compared to the treatment of exacerbations. An appreciation of the benefit of therapy should take count not only of survival curves but also of the quality of life. The indications for treatment should not neglect the possibility of therapeutic progress, sometimes unexpected. Intensive therapy may be justifiable in certain cases awaiting a lung transplant. ATB is only one part of treatment aimed strictly at the broncho-pulmonary system. Drainage and account of infectious agents other than classical bacterial infections or pathogenic mechanisms other than infections (nutritional problems, bronchial hyper-reactivity, immunological phenomenon, or primary or secondary inflammatory changes) should not be ignored.
Insights
Antibiotic use in cystic fibrosis (CF) requires clearer criteria. While antibiotics are crucial, their extensive use, especially prophylactic, needs re-evaluation, considering clinical benefit and quality of life.
Area of Science:
- Pulmonology
- Infectious Diseases
- Pharmacology
Background:
- Antibiotics remain vital for cystic fibrosis (CF) treatment, but current extensive usage lacks firm criteria.
- Prophylactic antibiotic use against Staphylococcus aureus (SA) or Haemophilus influenzae (HI) before Pseudomonas aeruginosa (PA) colonization is debated.
- The necessity of eradicating pathogens at all costs is uncertain pending further trials.
Purpose of the Study:
- To critically evaluate current antibiotic treatment strategies for cystic fibrosis (CF).
- To assess the efficacy and indications for antibiotic therapy in CF patients, considering various factors.
- To emphasize a holistic approach to CF management beyond solely focusing on bacterial infections.
Main Methods:
- Review of current clinical practices and existing literature on antibiotic use in CF.
- Analysis of the benefits and drawbacks of different antibiotic regimens, including prophylactic and exacerbation treatments.
- Consideration of patient survival and quality of life as key outcome measures.
Main Results:
- Continued antibiotic treatment (2-3 weeks) for SA and HI during exacerbations may offer durable clinical benefit, even in viral cases.
- Quarterly systemic anti-PA therapy has not shown definitive advantages over exacerbation treatment.
- Therapeutic decisions should integrate survival, quality of life, and potential for unexpected treatment advancements.
Conclusions:
- Antibiotic therapy is a component of CF care, but its application requires refined criteria.
- Management should encompass broader aspects like drainage, non-classical infections, and non-infectious mechanisms (e.g., nutritional, inflammatory).
- Further multi-center trials are needed to clarify optimal antibiotic strategies and the indispensability of pathogen eradication.